Literature DB >> 17279580

Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions.

Hagop M Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17279580     DOI： 10.1002/cncr.22502

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  8 in total

Review 1.  Acute myeloid leukemia: advancing clinical trials and promising therapeutics.

Authors:  Naval Daver; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi
Journal:  Expert Rev Hematol       Date:  2016-03-17       Impact factor: 2.929

Review 2.  Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

Authors:  Hagop Kantarjian; Susan O'Brien; Jorge Cortes; William Wierda; Stefan Faderl; Guillermo Garcia-Manero; Jean-Pierre Issa; Elihu Estey; Michael Keating; Emil J Freireich
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.

Authors:  Elias Jabbour; Hady Ghanem; Xuelin Huang; Farhad Ravandi; Guillermo Garcia-Manero; Susan O'Brien; Stephan Faderl; Sherry Pierce; Sangbum Choi; Srdan Verstovsek; Mark Brandt; Jorge Cortes; Hagop Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-11-15

4.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

Authors:  Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

5.  Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

Authors:  Hagop Kantarjian; Stefan Faderl; Guillermo Garcia-Manero; Selina Luger; Parameswaran Venugopal; Lori Maness; Meir Wetzler; Steven Coutre; Wendy Stock; David Claxton; Stuart L Goldberg; Martha Arellano; Stephen A Strickland; Karen Seiter; Gary Schiller; Elias Jabbour; Judy Chiao; William Plunkett
Journal:  Lancet Oncol       Date:  2012-10-15       Impact factor: 41.316

6.  A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

Authors:  Isam Abdel-Karim; William K Plunkett; Susan O'Brien; Francis Giles; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Min Du; Karen B Schneck; Victor J Chen; Boris K Lin; Steven J Nicol; Hagop M Kantarjian
Journal:  Invest New Drugs       Date:  2010-01-21       Impact factor: 3.850

7.  A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  N Daver; H Kantarjian; F Ravandi; E Estey; X Wang; G Garcia-Manero; E Jabbour; M Konopleva; S O'Brien; S Verstovsek; T Kadia; C Dinardo; S Pierce; X Huang; N Pemmaraju; M Diaz-Pines-Mateo; J Cortes; G Borthakur
Journal:  Leukemia       Date:  2015-09-14       Impact factor: 11.528

8.  The changing face of acute myeloid leukemia therapeutics in the elderly population.

Authors:  Naval Daver; Jorge Cortes
Journal:  South Asian J Cancer       Date:  2015 Jan-Mar
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.